Ocugen, Inc. - OCGN STOCK NEWS

Ocugen announced that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 1/2 clinical trial for OCU400, a modifier gene therapy candidate aimed at treating Retinitis Pigmentosa linked to NR2E3 and RHO mutations. The study recently dosed its first patient, and there were no serious adverse events reported. This therapy has the potential to address multiple retinal diseases with a single product, showcasing Ocugen's innovative approach in gene therapy.

Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman and CEO, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference on April 21, 2022, at 10:30 AM ET. The event will take place at the Hard Rock Hotel & Casino in Hollywood, Florida. A high-definition video webcast of the presentation will be available the next day on Ocugen’s website and Noble’s conference website. This event highlights Ocugen’s focus on advancing biotechnology and their innovative therapies.

Ocugen has expanded its agreement with Bharat Biotech to include the commercialization of COVAXIN™ in Mexico, granting it rights across North America. The vaccine is already authorized for emergency use in adults in Mexico and is under review for children aged 2-18. Dr. Shankar Musunuri, Ocugen's CEO, expressed optimism about the vaccine's role in combatting COVID-19 in Mexico. COVAXIN™ is noted for its robust immune response and logistical advantages. The agreement retains the same profit-sharing structure as in the U.S.

Ocugen announced that the FDA placed its Phase 2/3 immuno-bridging study for COVAXIN™ on clinical hold due to a voluntary pause in dosing participants. This decision follows the World Health Organization’s inspection of Bharat Biotech's manufacturing facility. The company aims to address the FDA's questions while evaluating these findings. Ocugen remains focused on advancing its innovative therapies and will collaborate with the FDA to resolve the clinical hold for OCU-002.

Ocugen, a biotechnology company, has commenced the Phase 1/2 clinical trial of OCU400 for treating retinitis pigmentosa (RP), marking its first clinical trial in humans for its modifier gene therapy platform. The first patient has been dosed in this observer-blind trial, which aims to evaluate safety and efficacy. RP, affecting approximately two million people globally, currently has no approved therapies. The trial focuses on genetic mutations in the NR2E3 and RHO genes, with potential future expansions to target more mutations.

Ocugen, Inc. (NASDAQ: OCGN) has appointed Dr. Marna C. Whittington to its Board of Directors, effective March 21, 2022. Dr. Whittington, a seasoned financial leader, previously served as CEO of Allianz Global Investors Capital and has held positions at Morgan Stanley and the University of Pennsylvania. Her expertise is expected to bolster Ocugen's growth strategy concerning its gene therapies and vaccine candidates. The announcement follows the departure of Manish Potti, who did not seek reappointment, expressing confidence in the company's future in addressing unmet medical needs.

Ocugen, Inc. (NASDAQ: OCGN) announced the appointment of Jessica Crespo as Chief Accounting Officer and Senior Vice President, Finance, effective March 18, 2022. With over 20 years of experience, Crespo previously served as Vice President, Corporate Controller, and Treasurer at Ocugen. Her responsibilities include financial strategy development and oversight of accounting and reporting functions. Chairman Dr. Shankar Musunuri emphasized her valuable contributions, crucial to sustaining the company’s growth as it advances therapies toward regulatory approval.

Ocugen announced on March 18, 2022, that its Board of Directors approved stock options for 331,155 shares and restricted stock units (RSUs) for 90,232 shares to nine new hires. The stock options, with a ten-year term, have an exercise price of $2.87 per share, aligning with the closing price on the grant date (March 16, 2022). Both options and RSUs will vest annually over three years, contingent on continued employment. This grant supports Ocugen's focus on gene therapies for blindness and COVID-19 vaccine development.

Ocugen, Inc. (NASDAQ: OCGN) announces that Dr. Shankar Musunuri, Chairman and CEO, will present at the 34th Annual Roth Conference on March 14, 2022, at 11:00 AM PT in Dana Point, CA. The event will feature meetings, analyst chats, and industry panels from approximately 400 companies. Ocugen focuses on gene therapies for retinal diseases and co-develops the COVID-19 vaccine candidate COVAXIN™. A live audio webcast of the presentation will be available on the company’s investor relations website.